PDCD1 and acute myeloid leukemia: In a phase Ib/II study that recruited 51 patients with AML that failed prior therapy, the combination of nivolumab, an anti-PD-1 antibody, and azacitidine demonstrated 18% CR and 15% hematologic improvement [115].